Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Low-dose aspirin may improve survival in patients with head and neck, lung cancers

What if a drug that sits in nearly everyone's medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing treatment for some head/neck and lung cancers.

19 Sep 2019

Mutations linked with sensitivity or resistance to immunotherapy in mNSCLC

The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

10 Sep 2019

New drug combination shows promise for treating non-small cell lung cancer patients

Patients with non-small cell lung cancer now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors.

27 Aug 2019

Super-powered immune cells to attack tumors

Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.

23 Aug 2019

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

20 Aug 2019

Preliminary study for detection of pancreatic cancer shows encouraging results

OTraces, Inc., a molecular diagnostics company specializing in early cancer detection, has announced completion of a preliminary study for detection of pancreatic cancer.

1 Aug 2019

Study finds specific direct targets for lung cancer treatment

A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.

29 Jul 2019

Salk study unlocks new way to target hard-to-treat cancers

Now, a new Salk Institute study, published on July 24, 2019, in the journal Science Advances, shows that researchers could target these hard-to-treat cancers by pursuing drugs that keep a cellular "switch," called CREB, from triggering tumor growth.

25 Jul 2019

MGH researchers identify potential markers of lung cancer

By examining both blood samples and tumor tissues from patients with non-small-cell lung cancer, investigators at Massachusetts General Hospital have identified markers that can distinguish between major subtypes of lung cancer and can accurately identify lung cancer stage.

16 Jul 2019

Alternate cell growth pathway could open door to new treatments for metastatic cancers

While researchers have a basic understanding of how primary cancer cells grow, less is known about metastasis, the deadly process by which cancers spread.

12 Jul 2019

Adding immunotherapy after initial treatment improves survival in metastatic NSCLC patients

Treating metastatic non-small cell lung cancer patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy – meaning all known sites of their cancer were either treated with surgery, radiation, or other definitive treatments – almost tripled the median progression-free survival compared to the historical average.

12 Jul 2019

Immune system could be blamed for ineffectiveness of high-dose radiation against lung cancer

When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better.

27 Jun 2019

Three beagles successfully identify lung cancer by scent, shows study

Three beagles successfully showed they are capable of identifying lung cancer by scent, a first step in identifying specific biomarkers for the disease.

18 Jun 2019

Radiation associated with increased risk of adverse cardiac events in lung cancer patients

As advances in the treatment of non-small cell lung cancer (NSCLC) extend patients' lives, more of these patients are facing a different threat: adverse cardiovascular events, such as heart attacks and heart failure.

11 Jun 2019

Roche Diagnostics launches first in vitro diagnostic ROS1 immunohistochemistry assay

Roche Diagnostics today announced the launch of the VENTANA ROS1 Antibody, the first and only in vitro diagnostic ROS1 immunohistochemistry assay. The test detects the presence of ROS1 protein in tissue, and may be useful in identifying ROS1-positive lung cancer cases.

From Roche Sequencing and Life Science 10 Jun 2019

Combination immunotherapy shows promise in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.

3 Jun 2019

Immunotherapy increases five-year survival rate of patients with advanced non-small cell lung cancer

In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years - and 25% of patients whose tumor cells had a specific protein lived at least that long.

3 Jun 2019

NCCN and AstraZeneca collaborate to improve care processes for lung cancer patients

The National Comprehensive Cancer Network Oncology Research Program and AstraZeneca, a global, science-led biopharmaceutical company, are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer.

31 May 2019

Pre-surgical neoadjuvant treatment shows promise in trial for patients with operable NSCLC

For patients with operable non-small cell lung cancer, pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, multicenter clinical trial involving investigators at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and nine other research centers